Home › Funds › ASHFORD CAPITAL MANAGEMENT INC › SUPN
ASHFORD CAPITAL MANAGEMENT INC position in SUPN
SUPERNUS PHARMACEUTICALS · Health Care
ASHFORD CAPITAL MANAGEMENT INC reported holding 613,783 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$28.5M, representing 3.06% of its reported portfolio and ranking #6 among its reported holdings. ASHFORD CAPITAL MANAGEMENT INC has disclosed SUPN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ASHFORD CAPITAL MANAGEMENT INC's SUPN position evolved
ASHFORD CAPITAL MANAGEMENT INC first disclosed a stake in SUPN in Q3 2023 at 916,747 shares (US$25.3M). The position peaked in Q1 2026 at 645,381 shares, worth US$33.4M. Across 12 filings, ASHFORD CAPITAL MANAGEMENT INC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 613,783 shares valued at US$28.5M — a reduction of -31,598 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 916.75K | $25.27M | New |
| Q4 2023 | 826.49K | $23.92M | Reduce |
| Q1 2024 | 763.47K | $26.04M | Reduce |
| Q2 2024 | 711.89K | $19.04M | Reduce |
| Q3 2024 | 544.03K | $16.96M | Reduce |
| Q4 2024 | 545.77K | $19.74M | Hold |
| Q1 2025 | 566.56K | $18.55M | Add |
| Q2 2025 | 574.37K | $18.10M | Add |
| Q3 2025 | 563.72K | $26.94M | Reduce |
| Q4 2025 | 612.54K | $30.44M | Add |
| Q1 2026 | 645.38K | $33.36M | Add |
| Q2 2026 | 613.78K | $28.55M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SUPN and 13F data
SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 34 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$123.1M), Sofinnova Investments, Inc. (US$48.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SUPN
- MILLENNIUM MANAGEMENT LLC 3.85M sh · $179.21M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.65M sh · $123.07M · Q2 2026
- Sofinnova Investments, Inc. 1.04M sh · $48.20M · Q2 2026
- Soleus Capital Management, L.P. 520.00K sh · $24.19M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 490.22K sh · $22.80M · Q2 2026
More on ASHFORD CAPITAL MANAGEMENT INC
FAQ
How long has ASHFORD CAPITAL MANAGEMENT INC held SUPN?
ASHFORD CAPITAL MANAGEMENT INC has disclosed SUPN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ASHFORD CAPITAL MANAGEMENT INC's current position in SUPN?
As of Q2 2026, ASHFORD CAPITAL MANAGEMENT INC holds 613.78K shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $28.55M, representing 3.06% of its reported portfolio and ranking #6.
Has ASHFORD CAPITAL MANAGEMENT INC been buying or selling SUPN?
In the latest 13F filing (Q2 2026), ASHFORD CAPITAL MANAGEMENT INC reduced its position in SUPN. The position peaked in Q1 2026 at 645.38K shares.
Which other funds hold SUPN?
Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, Sofinnova Investments, Inc., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.